Matthias Englbrecht

Lehrstuhl für Innere Medizin III

Prediction of Response to Certolizumab-Pegol in Rheumatoid Arthritis By Functional MRI of the Brain - an Interim Analysis of an Ongoing Investigator Initiated Phase III Trial (2017) Schenker H, Heß A, Konerth L, Sergeeva M, Prade J, Kleyer A, Reiser M, et al. Conference contribution INCREASE OF CORTICAL MICRO-CHANNELS (COMICS) AS A NEW FEATURE OF STRUCTURAL DAMAGE IN PAIENTS WITH RHEUMATOID ARTHRITIS (2017) Werner D, Simon D, Englbrecht M, Stemmler F, Berlin A, Haschka J, Renner N, et al. Conference contribution "Suddenly You Are a Person at Risk of Developing Rheumatoid Arthritis!" Different Perspectives of Individuals on Predictive Testing - Results of an International Qualitative Interview Study (2017) Mosor E, Stoffer M, Steiner G, Raza K, Stack RJ, Simons G, Falahee M, et al. Conference contribution Ustekinumab Is Superior to TNF Inhibitor Treatment in Resolving Enthesitis in Psa Patients with Active Enthesitis-Results from the Enthesial Clearance in Psoriatic Arthritis Study (2017) Guilhon de Araujo E, Englbrecht M, Höpken S, Finzel S, Hueber A, Rech J, Schett G Conference contribution MULTI-BIOMARKER DISEASE ACTIVITY AND AUTOANTIBODY STATUS LEAD TO COST EFFECTIVE TAPERING ALGORITHMS IN RHEUMATOID ARTHRITIS PATIENTS IN SUSTAINED REMISSION (2017) Hagen M, Englbrecht M, Haschka J, Reiser M, Kleyer A, Hueber A, Manger B, et al. Conference contribution QUANTIFICATION AND IMPACT OF SECONDARY OSTEOARTHRITIS USING HR-PQCT IN ANTI-CITRULLINATED PROTEIN ANTIBODY RHEUMATOID ARTHRITIS PATIENTS (2017) Figueiredo C, Simon D, Englbrecht M, Haschka J, Kleyer A, Bayat S, Hueber A, et al. Conference contribution Antimodified protein antibody response pattern influences the risk for disease relapse in patients with rheumatoid arthritis tapering disease modifying antirheumatic drugs (2017) Figueiredo CP, Bang H, Cobra JF, Englbrecht M, Hueber A, Haschka J, Manger B, et al. Journal article Safety and efficacy of intravenous cyclophosphamide pulse therapy in therapy refractory Crohn's disease patients (2017) Hirschmann S, Atreya R, Englbrecht M, Neurath M Journal article The revised Bristol Rheumatoid Arthritis Fatigue measures and the Rheumatoid Arthritis Impact of Disease scale: validation in six countries (2017) Hewlett S, Kirwan J, Bode C, Cramp F, Carmona L, Dures E, Englbrecht M, et al. Journal article The value of (18)F-FDG-PET/CT in identifying the cause of fever of unknown origin (FUO) and inflammation of unknown origin (IUO): data from a prospective study (2017) Schoenau V, Vogel K, Englbrecht M, Wacker J, Schmidt D, Manger B, Kuwert T, Schett G Journal article